Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Recruiting · NCT07389590 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 4 | 2026-05-06 | NCT07389590 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Johns Hopkins University | 579 |
| TG Therapeutics, Inc. | 16 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins University | Baltimore | United States | 150 |